The emergence of integrase drug resistance mutations has been observed in vitro and in patients experiencing virologic failure on raltegravir in clinical trials. Twenty three percent of patients receiving raltegravir in a clinical trial experienced virologic failure at 48 weeks and genotypic analysis detected raltegravir associated resistance mutations in 68% of virologic failures. This assay amplifies and sequences the HIV-1 integrase gene and reports mutations at positions associated with integrase inhibitor drug resistance.
2.0 mL FROZEN Plasma from a Lavender Top Tube - EDTA in a Plastic Vial
24 hours Ambient
5 days Refrigerated
35 days Frozen (Preferred)
Ship frozen.
Value of last viral load and date of last viral load must be provided with the order
Separate plasma from the cells by centrifugation within 24 hours after collection.
0.6 mL Plasma
Refer to Interpretive Results
The emergence of integrase drug resistance mutations has been observed in vitro and in patients experiencing virologic failure on raltegravir in clinical trials. Twenty three percent of patients receiving raltegravir in a clinical trial experienced virologic failure at 48 weeks and genotypic analysis detected raltegravir associated resistance mutations in 68% of virologic failures. This assay amplifies and sequences the HIV-1 integrase gene and reports mutations at positions associated with integrase inhibitor drug resistance.
5 to 8 days
00912601
87906